导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.42% | 1492/4534 |
| 近一周 | 1.38% | 2244/5179 |
| 近一月 | -3.99% | 2282/5111 |
| 近一季 | -5.65% | 2077/4939 |
| 近半年 | 0.85% | 1443/4676 |
| 近一年 | 5.80% | 1731/4214 |
| 近两年 | 61.48% | 1194/2861 |
| 近三年 | 33.75% | 926/2184 |
| 成立以来 | 30.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.94% 2568/4961 |
18.28% 1399/5312 |
- - |
- - |
| 2025 | 27.09% 1582/4813 |
0.73% 1780/3635 |
2.44% 1566/4076 |
26.25% 1355/4524 |
-2.44% 3150/4813 |
| 2024 | 9.07% 1496/3463 |
-1.53% 1238/2808 |
-3.27% 1331/3014 |
16.72% 1368/3129 |
-1.89% 1879/3463 |
| 2023 | -8.59% 1030/2656 |
7.49% 569/2280 |
-4.74% 1275/2385 |
-3.40% 916/2515 |
-7.58% 2173/2655 |
| 2022 | -23.71% 1160/2207 |
-15.78% 1068/1919 |
3.20% 1193/2016 |
-14.60% 1121/2113 |
2.78% 839/2208 |
| 2021 | 1.17% 686/1822 |
-2.89% 722/1255 |
9.35% 560/1330 |
-5.44% 805/1466 |
0.75% 1067/1822 |
| 2020 | 22.40% 673/1250 |
-9.57% 690/1028 |
14.49% 551/1067 |
7.57% 774/1164 |
9.91% 619/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.16% 743/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 汇添富中证长三角ETF联接A VS. 长安沪深300非周期A(740101) |